Debio 4228-201: Study of Extended Release GnRH in Newly Diagnosed Locally Advanced or Metastatic Prostate Cancer

Condition: Prostate Cancer

Sponsor: Debiopharm International SA

Full Title
Protocol Debio 4228-201: A Phase 2, randomized, open-Label, dose-finding study of Debio 4228, an extended-release formulation of gonadotropin-releasing hormone antagonist in participants with locally advanced/metastatic prostate cancer

Study Treatment
Debio 4228 - a 12 week extended release gonadotropin-releasing hormone antagonist (GnRH)

Eligibility/Info
- Locally advanced or metastatic prostate cancer
- No prior androgen deprivation therapy (ADT) or ≤6 months of treatment with ADT
- Eligible for continuous ADT

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage